PROCEPT BioRobotics Corp
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
PRCT$23.05+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss F-
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $136,191 | $75,014 | $34,473 |
| Cost of sales | 65,142 | 37,929 | 18,608 |
| Gross profit | 71,049 | 37,085 | 15,865 |
| Operating expenses: | |||
| Research and development | 48,446 | 28,981 | 18,993 |
| Selling, general and administrative | 131,773 | 88,828 | 51,036 |
| Total operating expenses | 180,219 | 117,809 | 70,029 |
| Loss from operations | (109,170) | (80,724) | (54,164) |
| Interest expense | (3,995) | (5,183) | (5,810) |
| Interest and other income, net | 7,268 | 2,011 | 121 |
| Loss on loan extinguishment | — | (3,258) | — |
| Net loss | $(105,897) | $(87,154) | $(59,853) |
| Net loss per share, basic and diluted | $(2.24) | $(1.96) | $(3.63) |
| Weighted-average common shares used to | |||
| compute net loss per share attributable to | |||
| common shareholders, basic and diluted | 47,255 | 44,400 | 16,480 |
| Other comprehensive gain (loss): | |||
| Unrealized gain (loss) on cash equivalents | 90 | 48 | (40) |
| Comprehensive loss | $(105,807) | $(87,106) | $(59,893) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.